- Home
- PEO vs DNTH Comparison
PEO vs DNTH Comparison
Compare PEO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEO
- DNTH
- Stock Information
- Founded
- PEO 1929
- DNTH 2015
- Country
- PEO United States
- DNTH United States
- Employees
- PEO N/A
- DNTH N/A
- Industry
- PEO Finance/Investors Services
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- PEO Finance
- DNTH Health Care
- Exchange
- PEO Nasdaq
- DNTH Nasdaq
- Market Cap
- PEO 596.4M
- DNTH 670.7M
- IPO Year
- PEO N/A
- DNTH N/A
- Fundamental
- Price
- PEO $22.18
- DNTH $22.29
- Analyst Decision
- PEO
- DNTH Strong Buy
- Analyst Count
- PEO 0
- DNTH 9
- Target Price
- PEO N/A
- DNTH $46.43
- AVG Volume (30 Days)
- PEO 35.4K
- DNTH 245.5K
- Earning Date
- PEO 01-01-0001
- DNTH 03-20-2025
- Dividend Yield
- PEO 5.93%
- DNTH N/A
- EPS Growth
- PEO N/A
- DNTH N/A
- EPS
- PEO N/A
- DNTH N/A
- Revenue
- PEO N/A
- DNTH $5,366,000.00
- Revenue This Year
- PEO N/A
- DNTH $100.14
- Revenue Next Year
- PEO N/A
- DNTH N/A
- P/E Ratio
- PEO N/A
- DNTH N/A
- Revenue Growth
- PEO N/A
- DNTH 51.41
- 52 Week Low
- PEO $19.22
- DNTH $18.35
- 52 Week High
- PEO $23.80
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- PEO 44.79
- DNTH 49.77
- Support Level
- PEO $21.68
- DNTH $21.28
- Resistance Level
- PEO $22.48
- DNTH $23.28
- Average True Range (ATR)
- PEO 0.42
- DNTH 1.75
- MACD
- PEO -0.12
- DNTH 0.17
- Stochastic Oscillator
- PEO 21.62
- DNTH 79.92
About PEO Adams Natural Resources Fund Inc.
Adams Natural Resources Fund Inc is a closed-end equity investment company specializing in energy and other natural resources stocks. The investment objectives of the fund are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. Its portfolio of investments comprises of different sector investments such as in the energy sector and basic materials.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.